Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sequella TB Drug Deal Blurs The Line Between Licensing And Financing

This article was originally published in Start Up

Executive Summary

For a small biotech seeking to out-license a promising asset in a far-flung territory, established pharmas typically make the best partners, given these big players have the infrastructure required to gain regulatory approval for a compound and bring it to market. But for Sequella Inc., a Rockville, MD-based infectious disease specialist, the commercial path of its tuberculosis drug in Russia and other former Soviet republics goes through a partner that will likely never sell the drug itself.
Advertisement

Related Content

Deals Of The Week: Tire-Kicking Season Continues Full-Swing
Atlas, CMEA Test New Biotech Model
Ascletis Raises Mammoth $100 Million To Deploy Its US-China Hybrid Model
Atlas, CMEA Test New Biotech Model
Ascletis Raises Mammoth $100 Million To Deploy Its US-China Hybrid Model
Lilly's Evolving Corporate Venture Model
Lilly's Evolving Corporate Venture Model
PanGenetics' NGF Antibody Sale Illustrates Index's Asset-Focused Strategy
PanGenetics' NGF Antibody Sale Illustrates Index's Asset-Focused Strategy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel